The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of MEK inhibition in neuroblastoma tumor cells.
Peter E. Zage
Research Funding - Novartis
Sarah Woodfield
No relevant relationships to disclose
Linna Zhang
No relevant relationships to disclose
Kathleen Scorsone
No relevant relationships to disclose